4-Chloro-3-methyl-1H-pyrazole-5-carbaldehyde, 95.0%, 1g

{2-[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]ethyl}amine trifluoroacetate, 95.0%, 10g

(2R,6S)-4-(tert-Butoxycarbonyl)-6-(hydroxymethyl)morpholine-2-carboxylic acid, 98%, 100mg

1-(3-Bromopyridin-2-yl)ethan-1-amine dihydrochloride, 97%, 250mg

GC capillary column ROTI®Cap-1701 MS, 30 m, 0.25 mm, 0.25 µm, 1 Piece(s)

Fmoc-D-Asn(Trt)-OH, 98.00%, 5g

tert-Butyl 4-[2-(aminomethyl)phenyl]piperazine-1-carboxylate, 95+%, 1g

5-Formyl-1-methyl-1H-pyrazole-4-carboxylic acid, 98%, 1g

N-Butylacrylamide, 95.0%, 250mg

2-Methyl-1-propanol, ROTICHROM® GC , 5 ml, glass packaging

3-morpholino-1-(3-nitrophenyl)-5,6-dihydropyridin-2(1H)-one, 98%, 1g

5,6,7,8-TETRAHYDROISOQUINOLINE, 97.0%, 1g

3-Chloro-2-ethynylpyridine, 250mg